{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:23:27Z","timestamp":1762899807733,"version":"3.45.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.euo.2019.06.013","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T17:56:42Z","timestamp":1562954202000},"page":"252-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Gu\u00e9rin?"],"prefix":"10.1016","volume":"3","author":[{"given":"Ashish M.","family":"Kamat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2019.06.013_bib0155","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.06.013_bib0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"year":"2019","series-title":"EAU Panel on NMIBC. European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS): 2019 update","author":"Babjuk","key":"10.1016\/j.euo.2019.06.013_bib0165"},{"key":"10.1016\/j.euo.2019.06.013_bib0170","unstructured":"FDA. FDA definition of BCG-unresponsive disease. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM529600.pdf."},{"issue":"6 Suppl. 1","key":"10.1016\/j.euo.2019.06.013_bib0175","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.euo.2019.06.013_bib0180","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0185","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0190","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000353089","article-title":"Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center","volume":"92","author":"Lazica","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2019.06.013_bib0200","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00345-017-2077-6","article-title":"Real-life experience\u2019: recurrence rate at 3 years with Hexvix(\u00ae) photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC\u2014a prospective controlled study","volume":"35","author":"Gallagher","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2019.06.013_bib0210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","article-title":"Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1G3)","volume":"27","author":"Hautmann","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0215","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0220","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle invasive bladder cancer","volume":"116","author":"Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2019.06.013_bib0225","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","article-title":"Treatment options available for bacillus Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer","volume":"62","author":"Yates","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2018.04.012","article-title":"Treatment options for patients with recurrent tumors after BCG therapy. Are we ignoring the obvious?","volume":"74","author":"Li","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0235","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2019.06.013_bib0240","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"Suppl. 8","key":"10.1016\/j.euo.2019.06.013_bib0245","first-page":"viii303","article-title":"Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): phase 2 KEYNOTE-057 trial","volume":"29","author":"de Wit","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2019.06.013_bib0250","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.eururo.2006.03.006","article-title":"Management of BCG \u201cfailures\u201d","volume":"49","author":"Palou Redorta","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0255","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet?. A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Euro Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.07.019","article-title":"T1G3 bladder cancer and bacillus Calmette-Gu\u00e9rin: tell me something we don\u2019t know","volume":"67","author":"Yates","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0265","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0270","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.juro.2016.01.087","article-title":"The timing of radical cystectomy for bacillus Calmette-Guerin failure and risk factors for prognosis","volume":"195","author":"Haas","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0275","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.juro.2010.01.025","article-title":"Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients","volume":"183","author":"Tilki","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumours who fail intravesical therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0285","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2016.02.031","article-title":"Papillary recurrence of bladder cancer at first evaluation after induction bacillus Calmette-Gu\u00e9rin therapy: implication for clinical trial design","volume":"70","author":"Mmeje","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.juro.2013.01.010","article-title":"Comparative performance of comorbidity indices for estimating perioperative and 5-year all-cause mortality following radical cystectomy for bladder cancer","volume":"190","author":"Boorjian","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0295","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.013_bib0300","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893111930094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893111930094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:45:24Z","timestamp":1762875924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893111930094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S258893111930094X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2019.06.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"type":"print","value":"2588-9311"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Gu\u00e9rin?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2019.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}